| BioWorld

Archemix Could Get $315M in Baxter Hemophilia Assets Deal

Inspiration Starts Hemophilia Phase II/III, Collects $50M

Somaxon Adding $26M; Sales Efforts for Silenor Under Way

White House Honors Top U.S. Scientists, Innovators

Amgen Wins D-Mab OK for Fractures in Cancer Patients

WASHINGTON – The FDA late Thursday approved Amgen Inc.'s denosumab 120 mg as a therapy to prevent skeletal-related events (SRE) in patients with bone metastases from solid tumors. (BioWorld Today) Read More

BTG Grabs Biocompatibles for $284.5M in All-Share Deal

BioWorld

Nov. 22, 2010

Archemix Could Get $315M in Baxter Hemophilia Assets Deal

Inspiration Starts Hemophilia Phase II/III, Collects $50M

Somaxon Adding $26M; Sales Efforts for Silenor Under Way

Stock Movers

White House Honors Top U.S. Scientists, Innovators

Clinic Roundup

Other News To Note

EORTC Roundup

Bench Press

Amgen Wins D-Mab OK for Fractures in Cancer Patients

BTG Grabs Biocompatibles for $284.5M in All-Share Deal

Today's news in brief

Today's news in brief

News in brief

In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

Pan-cancer proteome atlas reveals new biomarkers and targets